Literature DB >> 21960919

Certolizumab Pegol for Moderate-to-Severe Crohn's Disease.

William J Sandborn1.   

Abstract

Entities:  

Year:  2008        PMID: 21960919      PMCID: PMC3096126     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


× No keyword cloud information.
  3 in total

1.  A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.

Authors:  Stefan Schreiber; Paul Rutgeerts; Richard N Fedorak; Munaa Khaliq-Kareemi; Michael A Kamm; Michel Boivin; Charles N Bernstein; Michael Staun; Ole Østergaard Thomsen; Alison Innes
Journal:  Gastroenterology       Date:  2005-09       Impact factor: 22.682

2.  Certolizumab pegol for the treatment of Crohn's disease.

Authors:  William J Sandborn; Brian G Feagan; Simeon Stoinov; Pieter J Honiball; Paul Rutgeerts; David Mason; Ralph Bloomfield; Stefan Schreiber
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

3.  Maintenance therapy with certolizumab pegol for Crohn's disease.

Authors:  Stefan Schreiber; Mani Khaliq-Kareemi; Ian C Lawrance; Ole Østergaard Thomsen; Stephen B Hanauer; Juliet McColm; Ralph Bloomfield; William J Sandborn
Journal:  N Engl J Med       Date:  2007-07-19       Impact factor: 91.245

  3 in total
  1 in total

1.  Certolizumab pegol for induction of remission in Crohn's disease.

Authors:  Hajime Yamazaki; Ryuhei So; Katsuyoshi Matsuoka; Taku Kobayashi; Shinichiro Shinzaki; Minoru Matsuura; Shinji Okabayashi; Yuki Kataoka; Yasushi Tsujimoto; Toshi A Furukawa; Norio Watanabe
Journal:  Cochrane Database Syst Rev       Date:  2019-08-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.